BRAF and metastatic melanoma: Providing further relevance for visfatin in the progression of melanoma, its elevated levels were found in the serum of patients with BRAF-mutated metastatic melanoma with decreasing concentrations in response to BRAF/MEK inhibitor therapy [228].